verapamil (Q410291)

VERAPAMIL (English)

3 October 2016

C₂₇H₃₈N₂O₄

1 reference

VERAPAMIL (English)

19 November 2016

CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC

1 reference

Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.

VERAPAMIL (English)

19 November 2016

1 reference

14 February 2018

1 reference

14 February 2018

1 reference

14 February 2018

1 reference

Floricola striata

1 reference

Cytotoxic p-Terphenyls from the Endolichenic Fungus Floricola striata

Chrysosporium

1 reference

Chrysosporazines F-M: P-Glycoprotein Inhibitory Phenylpropanoid Piperazines from an Australian Marine Fish Derived Fungus, Chrysosporium sp. CMB-F294

medical condition treated

myocardial infarction

1 reference

13 December 2016

2 references

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

1 reference

13 December 2016

arterial hypertension

2 references

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

1 reference

supraventricular tachycardia

13 December 2016

1 reference

Food and Drug Administration

13 December 2016

essential hypertension

start time

11 August 1981

approved by

1 reference

Inxight: Drugs Database

https://drugs.ncats.io/drug/CJ0O37KU29

2 November 2018

reference URL

http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018817s032lbl.pdf

significant drug interaction

(RS)-metoprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nadolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atenolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nebivolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

acebutolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

betaxolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bisoprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pindolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

carvedilol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

propranolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

labetalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celiprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

esmolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levobunolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fingolimod

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-metoprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nadolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atenolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nebivolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

acebutolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

betaxolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bisoprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pindolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

carvedilol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

propranolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

labetalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celiprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

esmolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levobunolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

terazosin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prazosin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

domperidone

long QT syndrome

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dantrolene

circulatory collapse

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dantrolene

hyperkalemia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

digoxin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

flecainide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clonidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ivabradine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vardenafil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

guanfacine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clonidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

avanafil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bromocriptine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

disopyramide

myocardial depression

1 reference

A reference set of clinically relevant adverse drug-drug interactions

myocardial depression

1 reference

A reference set of clinically relevant adverse drug-drug interactions

flecainide

myocardial depression

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sinoatrial arrest

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

A reference set of clinically relevant adverse drug-drug interactions

digoxin

third-degree atrioventricular block

1 reference

A reference set of clinically relevant adverse drug-drug interactions

digoxin

toxicity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

disopyramide

congestive heart failure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

simvastatin

rhabdomyolysis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

simvastatin

muscular disease

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atorvastatin

rhabdomyolysis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atorvastatin

muscular disease

1 reference

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cardiotoxicity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ritonavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cyclosporine

kidney failure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cyclosporine

cholestasis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cyclosporine

paresthesia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fingolimod

atrioventricular block

1 reference

A reference set of clinically relevant adverse drug-drug interactions

xerostomia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

urinary retention

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sedation

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

Calcium voltage-gated channel subunit alpha1 S

1 reference

Calcium voltage-gated channel subunit alpha1 C

17 August 2016

1 reference

Calcium voltage-gated channel subunit alpha1 D

17 August 2016

1 reference

Voltage-dependent L-type calcium channel subunit alpha-1F

17 August 2016

1 reference

cytochrome P450 family 3 subfamily A member 4

17 August 2016

1 reference

Potassium inwardly-rectifying channel, subfamily J, member 6

17 August 2016

1 reference

Potassium voltage-gated channel subfamily A member 7

17 August 2016

1 reference

Potassium voltage-gated channel subfamily A member 10

17 August 2016

1 reference

Sodium leak channel, non-selective

17 August 2016

1 reference

Solute carrier family 29 member 4

17 August 2016

1 reference

Two pore segment channel 1

17 August 2016

1 reference

Two pore segment channel 2

17 August 2016

1 reference

intravenous infusion and defusion

17 August 2016

route of administration

oral administration

0 references

0 references

pregnancy category

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category B

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Verapamil

last update

11 January 2017

calcium channel blocker

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

D014700

xenobiotic-transporting ATPase inhibitor

15 March 2018

1 reference

5 March 2018

1 reference

Medical Subject Headings

15 March 2018

1 reference

Medical Subject Headings

15 March 2018

0 references

2926.90.11

0 references

0 references

0 references

Verapamil

0 references

Identifiers

InChI

InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3

1 reference

VERAPAMIL (English)

19 November 2016

2 references

VERAPAMIL (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

52-53-9

2 references

verapamil (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=52-53-9

9 April 2021

1 reference

Verapamil (English)

3 October 2016

2 references

VERAPAMIL (English)

19 November 2016

Reaxys registry number

2825000

0 references

ChEBI ID

77733

mapping relation type

2 references

VERAPAMIL (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3

1 reference

VERAPAMIL (English)

19 November 2016

2 references

inferred from InChIKey

SCHEMBL16742

2 references

based on heuristic

inferred from InChIKey

MSBNK-Athens_Univ-AU226001

1 reference

MassBank accession ID

SM855703

0 references

0 references

MSBNK-Athens_Univ-AU226002

0 references

MSBNK-Athens_Univ-AU226003

0 references

MSBNK-Athens_Univ-AU226004

0 references

MSBNK-Athens_Univ-AU226005

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

MSBNK-Keio_Univ-KO004261

0 references

MSBNK-Keio_Univ-KO004262

0 references

MSBNK-Keio_Univ-KO004263

0 references

MSBNK-Keio_Univ-KO004264

0 references

MSBNK-Keio_Univ-KO004265

0 references

MSBNK-Keio_Univ-KO009311

0 references

MSBNK-Keio_Univ-KO009312

0 references

MSBNK-Keio_Univ-KO009313

0 references

MSBNK-Keio_Univ-KO009314

0 references

MSBNK-Keio_Univ-KO009315

0 references

0 references

0 references

0 references

0 references

MSBNK-Washington_State_Univ-BML00815

0 references

MSBNK-Washington_State_Univ-BML00825

0 references

MSBNK-Washington_State_Univ-BML00835

0 references

MSBNK-Washington_State_Univ-BML82330

0 references

MSBNK-Washington_State_Univ-BML82331

0 references

MSBNK-Washington_State_Univ-BML82332

0 references

MSBNK-Waters-WA000603

0 references

MSBNK-Waters-WA000604

0 references

MSBNK-Waters-WA000605

0 references

MSBNK-Waters-WA000606

0 references

MSBNK-Waters-WA000607

0 references

SPLASH

splash10-0a4i-0000900000-e6a2b357160bf5b92c22

0 references

splash10-066r-0902400000-d8eac2ccd0a767c7e432

0 references

splash10-014i-0901000000-688f3c2345c5d9ccb8a5

0 references

splash10-014i-0900000000-cd09f8a2be876936f662

0 references

splash10-0uxr-0918000000-76641dd6dbc5cb05e79a

0 references

splash10-0a4i-0000900000-05ea95eb1f39b6515212

0 references

splash10-066r-0902600000-a675e624692c25472ce8

0 references

splash10-014i-0901000000-70d820628d2613557239

0 references

splash10-0gb9-0900000000-e3ca24cf75d574df08a8

0 references

splash10-0uyi-0900000000-f3a9fa002c56d3e5689a

0 references

splash10-0zg0-2900000000-101e077b890671063633

0 references

splash10-0a4i-0000900000-84b4516ac84e6912cc15

0 references

splash10-066r-0902600000-bc1701c307e45ee4dcd7

0 references

splash10-014i-0901000000-6fbdab598bcb6147a4bf

0 references

splash10-0gb9-0900000000-ce61116806eaa908681c

0 references

splash10-0uxr-0900000000-ad3f25e02a7c8e66fb6a

0 references

splash10-0zgr-2900000000-792b9009086561f6c398

0 references

splash10-0uxr-0918000000-e7a5a3f8c88dc40683fd

0 references

splash10-0a4i-0000900000-4cde9a4b3a4f83d16afc

0 references

splash10-0a4i-0000900000-9a5c5240148f82cc6add

0 references

splash10-066r-0902800000-ae024239c46b33917426

0 references

splash10-014i-0901000000-81d1159b3102cff76218

0 references

splash10-014i-0900000000-2411d65dfe09741dde81

0 references

splash10-0gb9-0914000000-0463345a8ab0de7aa99e

0 references

splash10-03di-0390000000-f41d80462c5d06c4f001

0 references

splash10-0097-2980000000-80c36ebc69fab43b78f5

0 references

splash10-0uxr-0900000000-252a9989a8511cb2db80

0 references

splash10-0f79-0900000000-4fd6ca2c6c19c3bbf8f0

0 references

splash10-014i-0900000000-42074ab645b7af0ef79f

0 references

splash10-0zgi-0900000000-20360f78435d5f482709

0 references

splash10-0uxr-0819000000-7f68ebd6e344adf12101

0 references

splash10-0uxr-0918000000-d3727bbe601b80eabfb3

0 references

splash10-0a4i-0100900000-0a928f78000f291f031d

0 references

splash10-066r-0902600000-40f800e4a364d9ca214c

0 references

splash10-0gb9-0900000000-4dea228d69d59705fc18

0 references

splash10-0a4i-0000900000-edc089a33f40e30b1ccc

0 references

splash10-03di-0000090000-1f6045a4509201805f96

0 references

splash10-0a4i-0000900000-fd9ad348a1634d9d0e78

0 references

splash10-066r-0900300000-47a59c15bdbcbc62d6c6

0 references

splash10-0udi-3519000000-b5e0b9e0caac5cb57222

0 references

splash10-004l-0702900000-6a46ea2d5eed6d8b01eb

0 references

splash10-0006-4109800000-80d342090a0be3344e82

0 references

splash10-054w-0954400000-2def387c7c93ab211423

0 references

HSDB ID

3928

1 reference

Hazardous Substances Data Bank

28 October 2019

Verapamil (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

1 reference

verapamil (English)

ECHA Substance Infocard ID

19 November 2016

100.000.133

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

Verapamil (English)

CAS no.: 52-53-9 (English)

1 reference

Verapamil (English)

publication date

17 November 2015

1 reference

verapamil (English)

19 November 2016

Verapamil

0 references

0 references

1 reference

verapamil (English)

19 November 2016

1 reference

Human Metabolome Database ID

HMDB0001850

2 references

based on heuristic

inferred from InChIKey

2 references

verapamil (English)

19 November 2016

MedlinePlus drug identifier

a684030

0 references

PatientsLikeMe treatment ID

0 references

1 reference

verapamil (English)

19 November 2016

0 references

1 reference

1 reference

2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile (English)

3 October 2016

1 reference

California Proposition 65 list of chemicals

2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile (English)

3 October 2016

1 reference

https://oehha.ca.gov/chemicals/verapamil

7 January 2020

reference URL

electronic Essential Medicines List medicine ID

133

1 reference

reference URL

https://list.essentialmeds.org/medicines/133

eEML - Electronic Essential Medicines List (English)

Encyclopædia Britannica Online ID

23 October 2021

science/verapamil

subject named as

verapamil

0 references

1 reference

28 October 2013

1 reference

9 July 2020

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

Römpp online ID

RD-22-00300

1 reference

imported from Wikimedia project

1 reference